Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Neurology
Published in: Journal of Neurology 4/2011

01-04-2011 | Original Communication

Management of punding in Parkinson’s disease: an open-label prospective study

Authors: A. Fasano, L. Ricciardi, M. Pettorruso, A. R. Bentivoglio

Published in: Journal of Neurology | Issue 4/2011

Login to get access

Abstract

Punding, a peculiar stereotyped behavior characterized by intense fascination with complex, excessive, non-goal-oriented, repetitive activities, is a quite rare condition complicating Parkinson’s disease (PD). It is triggered by dopaminergic therapy and could have a strong impact on patient quality of life. No study has specifically investigated medical management of this condition, and only a few anecdotal reports have provided therapeutic hints. Given the suggested similarities to drug-induced dyskinesias, we have previously suggested a multistep algorithm for management of punding. We conducted a prospective open-label study on ten PD punders aimed at testing its validity. In two cases, reduction of levodopa therapy was efficacious; amantadine was effective in controlling punding in four cases; in the remaining cases, quetiapine was employed, with mild efficacy in two cases.
Literature
1.
Evans AH, Katzenschlager R, Paviour D, O’Sullivan JD, Appel S, Lawrence AD, Lees AJ (2004) Punding in Parkinson’s disease: its relation to the dopamine dysregulation syndrome. Mov Disord 19:397–405PubMedCrossRef
2.
Fasano A, Petrovic I (2010) Insights into pathophysiology of punding reveal possible treatment strategies. Mol Psychiatry 15:560–573PubMedCrossRef
3.
Rylander G (1972) Psychoses and the punding and choreiform syndromes in addiction to central stimulant drugs. Psychiatr Neurol Neurochir 75:203–212PubMed
4.
Fasano A, Barra A, Nicosia P, Rinaldi F, Bria P, Bentivoglio AR, Tonioni F (2008) Cocaine addiction: from habits to stereotypical-repetitive behaviors and punding. Drug Alcohol Depend 96:178–182PubMedCrossRef
5.
6.
7.
(2002) Amantadine and other antiglutamate agents: management of Parkinson’s disease. Mov Disord 17 (Suppl 4):13–22
8.
Kashihara K, Imamura T (2008) Amantadine may reverse punding in Parkinson’s disease—observation in a patient. Mov Disord 23:129–130PubMedCrossRef
9.
Jankovic J (2005) Motor fluctuations and dyskinesias in Parkinson’s disease: clinical manifestations. Mov Disord 20 (Suppl 11):11–16
10.
Silveira-Moriyama L, Evans AH, Katzenschlager R, Lees AJ (2006) Punding and dyskinesias. Mov Disord 21:2214–2217PubMedCrossRef
11.
Gelb DJ, Oliver E, Gilman S (1999) Diagnostic criteria for Parkinson disease. Arch Neurol 56:33–39PubMedCrossRef
12.
Aubert I, Guigoni C, Hakansson K, Li Q, Dovero S, Barthe N, Bioulac BH, Gross CE, Fisone G, Bloch B, Bezard E (2005) Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann Neurol 57:17–26PubMedCrossRef
13.
Kimber TE, Thompson PD, Kiley MA (2008) Resolution of dopamine dysregulation syndrome following cessation of dopamine agonist therapy in Parkinson’s disease. J Clin Neurosci 15:205–208PubMedCrossRef
14.
15.
Thomas A, Bonanni L, Gambi F, Di Iorio A, Onofrj M (2010) Pathological gambling in PD is reduced by amantadine. Ann Neurol (in press)
16.
Fasano A, Elia AE, Soleti F, Guidubaldi A, Bentivoglio AR (2006) Punding and computer addiction in Parkinson’s disease. Mov Disord 21:1217–1218PubMedCrossRef
17.
Miwa H, Morita S, Nakanishi I, Kondo T (2004) Stereotyped behaviors or punding after quetiapine administration in Parkinson’s disease. Parkinsonism Relat Disord 10:177–180PubMedCrossRef
18.
Durif F, Vidailhet M, Assal F, Roche C, Bonnet AM, Agid Y (1997) Low-dose clozapine improves dyskinesias in Parkinson’s disease. Neurology 48:658–662PubMed
19.
Fasano A, Pettorruso M, Ricciardi L, Conte G, Bentivoglio AR (2010) Punding in Parkinson’s disease: the impact of patient’s awareness on diagnosis. Mov Disord 25:1297–1299PubMedCrossRef
Metadata
Title
Management of punding in Parkinson’s disease: an open-label prospective study
Authors
A. Fasano
L. Ricciardi
M. Pettorruso
A. R. Bentivoglio
Publication date
01-04-2011
Publisher
Springer-Verlag
Published in
Journal of Neurology / Issue 4/2011
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-010-5817-8

Other articles of this Issue 4/2011

Journal of Neurology 4/2011 Go to the issue

Original Communication

Widespread extrahippocampal NAA/(Cr+Cho) abnormalities in TLE with and without mesial temporal sclerosis

Letter to the Editors

Herpes simplex virus type 2 meningitis and symptomatic migraine

Original Communication

Urinary symptoms and urodynamic findings in patients with Machado–Joseph disease

Original Communication

Gait variability in Parkinson’s disease: an indicator of non-dopaminergic contributors to gait dysfunction?

Original Communication

Effect of 4-aminopyridine on gravity dependence and neural integrator function in patients with idiopathic downbeat nystagmus

Original Communication

Basal ganglia hyperechogenicity does not distinguish between patients with primary dystonia and healthy individuals